At the same time, the authors demonstrated that the identified variant resulted in downregulation of FBXW7 and loss of function (Meier-Abt et al., 2024), which provided empirical evidence that patients with DEDHIL may have increased tumor susceptibility. This evidence concerns the gene FBXW7 and neoplasm.